Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1–5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues

go back to reference Beckers A, Aaltonen LA, Daly AF, Karhu A (2013) Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 34(2):239–277. https://doi.org/10.1210/er.2012-1013 CrossRefPubMedPubMedCentral Beckers A, Aaltonen LA, Daly AF, Karhu A (2013) Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 34(2):239–277. https://​doi.​org/​10.​1210/​er.​2012-1013 CrossRefPubMedPubMedCentral

go back to reference Daly AF, Beckers A (2015)Familial isolated pituitary adenomas (FIPA) and mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocrinol Metab Clin 44(1):19–25. https://doi.org/10.1016/j.ecl.2014.10.002 CrossRef Daly AF, Beckers A (2015)Familial isolated pituitary adenomas (FIPA) and mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocrinol Metab Clin 44(1):19–25. https://​doi.​org/​10.​1016/​j.​ecl.​2014.​10.​002 CrossRef

go back to reference Daly AF, Beckers A (2017) The role of AIP mutations in pituitary adenomas: 10 years on. Endocrine 55(2):333–335. https://doi.org/10.1007/s12020-016-1194-0 CrossRefPubMed Daly AF, Beckers A (2017) The role of AIP mutations in pituitary adenomas: 10 years on. Endocrine 55(2):333–335. https://​doi.​org/​10.​1007/​s12020-016-1194-0 CrossRefPubMed

go back to reference Niyazoglu M, Sayitoglu M, Firtina S, Hatipoglu E, Gazioglu N, Kadioglu P (2014) Familial acromegaly due to aryl hydrocarbon receptor-interacting protein (AIP) gene mutation in a Turkish cohort. Pituitary 17(3):220–226. https://doi.org/10.1007/s11102-013-0493-1 CrossRefPubMed Niyazoglu M, Sayitoglu M, Firtina S, Hatipoglu E, Gazioglu N, Kadioglu P (2014) Familial acromegaly due to aryl hydrocarbon receptor-interacting protein (AIP) gene mutation in a Turkish cohort. Pituitary 17(3):220–226. https://​doi.​org/​10.​1007/​s11102-013-0493-1 CrossRefPubMed

go back to reference Yarman S, Ogret YD, Oguz FS (2015) Do the aryl hydrocarbon receptor interacting protein variants (Q228K and Q307R) play a role in patients with familial and sporadic hormone-secreting pituitary adenomas? Genet Test Mol Biomark 19(7):394–398. https://doi.org/10.1089/gtmb.2014.0333 CrossRef Yarman S, Ogret YD, Oguz FS (2015) Do the aryl hydrocarbon receptor interacting protein variants (Q228K and Q307R) play a role in patients with familial and sporadic hormone-secreting pituitary adenomas? Genet Test Mol Biomark 19(7):394–398. https://​doi.​org/​10.​1089/​gtmb.​2014.​0333 CrossRef

go back to reference Lloyd C, Grossman A (2014) The AIP (aryl hydrocarbon receptor-interacting protein) gene and its relation to the pathogenesis of pituitary adenomas. Endocrine 46(3):387–396. https://doi.org/10.1007/s12020-013-0125-6 CrossRefPubMed Lloyd C, Grossman A (2014) The AIP (aryl hydrocarbon receptor-interacting protein) gene and its relation to the pathogenesis of pituitary adenomas. Endocrine 46(3):387–396. https://​doi.​org/​10.​1007/​s12020-013-0125-6 CrossRefPubMed

go back to reference Cazabat L, Libe R, Perlemoine K, Rene-Corail F, Burnichon N, Gimenez-Roqueplo AP, Dupasquier-Fediaevsky L, Bertagna X, Clauser E, Chanson P, Bertherat J, Raffin-Sanson ML (2007) Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur J Endocrinol 157(1):1–8. https://doi.org/10.1530/eje-07-0181 CrossRefPubMed Cazabat L, Libe R, Perlemoine K, Rene-Corail F, Burnichon N, Gimenez-Roqueplo AP, Dupasquier-Fediaevsky L, Bertagna X, Clauser E, Chanson P, Bertherat J, Raffin-Sanson ML (2007) Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur J Endocrinol 157(1):1–8. https://​doi.​org/​10.​1530/​eje-07-0181 CrossRefPubMed

go back to reference Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, Urban JD, Petrossians P, Elenkova A, Tabarin A, Desailloud R, Maiter D, Schurmeyer T, Cozzi R, Theodoropoulou M, Sievers C, Bernabeu I, Naves LA, Chabre O, Montanana CF, Hana V, Halaby G, Delemer B, Aizpun JI, Sonnet E, Longas AF, Hagelstein MT, Caron P, Stalla GK, Bours V, Zacharieva S, Spada A, Brue T, Beckers A (2011) High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol 165(4):509–515. https://doi.org/10.1530/eje-11-0304 CrossRefPubMed Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, Urban JD, Petrossians P, Elenkova A, Tabarin A, Desailloud R, Maiter D, Schurmeyer T, Cozzi R, Theodoropoulou M, Sievers C, Bernabeu I, Naves LA, Chabre O, Montanana CF, Hana V, Halaby G, Delemer B, Aizpun JI, Sonnet E, Longas AF, Hagelstein MT, Caron P, Stalla GK, Bours V, Zacharieva S, Spada A, Brue T, Beckers A (2011) High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol 165(4):509–515. https://​doi.​org/​10.​1530/​eje-11-0304 CrossRefPubMed

go back to reference Karaca Z, Taheri S, Tanriverdi F, Unluhizarci K, Kelestimur F (2015) Prevalence of AIP mutations in a series of Turkish acromegalic patients: are synonymous AIP mutations relevant? Pituitary 18(6):831–837. https://doi.org/10.1007/s11102-015-0659-0 CrossRefPubMed Karaca Z, Taheri S, Tanriverdi F, Unluhizarci K, Kelestimur F (2015) Prevalence of AIP mutations in a series of Turkish acromegalic patients: are synonymous AIP mutations relevant? Pituitary 18(6):831–837. https://​doi.​org/​10.​1007/​s11102-015-0659-0 CrossRefPubMed

go back to reference Rostomyan L, Daly AF, Petrossians P, Nachev E, Lila AR, Lecoq AL, Lecumberri B, Trivellin G, Salvatori R, Moraitis AG, Holdaway I, Kranenburg-van Klaveren DJ, Chiara Zatelli M, Palacios N, Nozieres C, Zacharin M, Ebeling T, Ojaniemi M, Rozhinskaya L, Verrua E, Jaffrain-Rea ML, Filipponi S, Gusakova D, Pronin V, Bertherat J, Belaya Z, Ilovayskaya I, Sahnoun-Fathallah M, Sievers C, Stalla GK, Castermans E, Caberg JH, Sorkina E, Auriemma RS, Mittal S, Kareva M, Lysy PA, Emy P, De Menis E, Choong CS, Mantovani G, Bours V, De Herder W, Brue T, Barlier A, Neggers SJ, Zacharieva S, Chanson P, Shah NS, Stratakis CA, Naves LA, Beckers A (2015) Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer 22(5):745–757. https://doi.org/10.1530/erc-15-0320 CrossRefPubMed Rostomyan L, Daly AF, Petrossians P, Nachev E, Lila AR, Lecoq AL, Lecumberri B, Trivellin G, Salvatori R, Moraitis AG, Holdaway I, Kranenburg-van Klaveren DJ, Chiara Zatelli M, Palacios N, Nozieres C, Zacharin M, Ebeling T, Ojaniemi M, Rozhinskaya L, Verrua E, Jaffrain-Rea ML, Filipponi S, Gusakova D, Pronin V, Bertherat J, Belaya Z, Ilovayskaya I, Sahnoun-Fathallah M, Sievers C, Stalla GK, Castermans E, Caberg JH, Sorkina E, Auriemma RS, Mittal S, Kareva M, Lysy PA, Emy P, De Menis E, Choong CS, Mantovani G, Bours V, De Herder W, Brue T, Barlier A, Neggers SJ, Zacharieva S, Chanson P, Shah NS, Stratakis CA, Naves LA, Beckers A (2015) Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer 22(5):745–757. https://​doi.​org/​10.​1530/​erc-15-0320 CrossRefPubMed

go back to reference Kasuki L, Colli LM, Elias PC, Castro M, Gadelha MR (2012) Resistance to octreotide LAR in acromegalic patients with high SSTR2 expression: analysis of AIP expression. Arq Bras Endocrinol Metab 56(8):501–506CrossRef Kasuki L, Colli LM, Elias PC, Castro M, Gadelha MR (2012) Resistance to octreotide LAR in acromegalic patients with high SSTR2 expression: analysis of AIP expression. Arq Bras Endocrinol Metab 56(8):501–506CrossRef

go back to reference Kasuki L, Vieira Neto L, Wildemberg LE, Colli LM, de Castro M, Takiya CM, Gadelha MR (2012) AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer 19(3):L25-29. https://doi.org/10.1530/erc-12-0020 CrossRef Kasuki L, Vieira Neto L, Wildemberg LE, Colli LM, de Castro M, Takiya CM, Gadelha MR (2012) AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer 19(3):L25-29. https://​doi.​org/​10.​1530/​erc-12-0020 CrossRef

go back to reference Kasuki Jomori de Pinho L, Vieira Neto L, Armondi Wildemberg LE, Gasparetto EL, Marcondes J, de Almeida Nunes B, Takiya CM, Gadelha MR (2011) Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Neuroendocrinology 94(1):39–48. https://doi.org/10.1159/000322787 CrossRefPubMed Kasuki Jomori de Pinho L, Vieira Neto L, Armondi Wildemberg LE, Gasparetto EL, Marcondes J, de Almeida Nunes B, Takiya CM, Gadelha MR (2011) Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Neuroendocrinology 94(1):39–48. https://​doi.​org/​10.​1159/​000322787 CrossRefPubMed

go back to reference Jaffrain-Rea ML, Rotondi S, Turchi A, Occhi G, Barlier A, Peverelli E, Rostomyan L, Defilles C, Angelini M, Oliva MA, Ceccato F, Maiorani O, Daly AF, Esposito V, Buttarelli F, Figarella-Branger D, Giangaspero F, Spada A, Scaroni C, Alesse E, Beckers A (2013) Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. Endocr Relat Cancer 20(5):753–766. https://doi.org/10.1530/erc-12-0322 CrossRefPubMed Jaffrain-Rea ML, Rotondi S, Turchi A, Occhi G, Barlier A, Peverelli E, Rostomyan L, Defilles C, Angelini M, Oliva MA, Ceccato F, Maiorani O, Daly AF, Esposito V, Buttarelli F, Figarella-Branger D, Giangaspero F, Spada A, Scaroni C, Alesse E, Beckers A (2013) Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. Endocr Relat Cancer 20(5):753–766. https://​doi.​org/​10.​1530/​erc-12-0322 CrossRefPubMed

go back to reference Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to Somatostatin Analogs in Acromegaly. Endocr Rev 32(2):247–271. https://doi.org/10.1210/er.2010-0002 CrossRefPubMed Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to Somatostatin Analogs in Acromegaly. Endocr Rev 32(2):247–271. https://​doi.​org/​10.​1210/​er.​2010-0002 CrossRefPubMed

go back to reference Paragliola RM, Corsello SM, Salvatori R (2017) Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance. Pituitary 20(1):109–115. https://doi.org/10.1007/s11102-016-0768-4 CrossRefPubMed Paragliola RM, Corsello SM, Salvatori R (2017) Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance. Pituitary 20(1):109–115. https://​doi.​org/​10.​1007/​s11102-016-0768-4 CrossRefPubMed

go back to reference Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951. https://doi.org/10.1210/jc.2014-2700 CrossRefPubMed Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951. https://​doi.​org/​10.​1210/​jc.​2014-2700 CrossRefPubMed

go back to reference Ozkaya HM, Comunoglu N, Keskin FE, Oz B, Haliloglu OA, Tanriover N, Gazioglu N, Kadioglu P (2016) Locally produced estrogen through aromatization might enhance tissue expression of pituitary tumor transforming gene and fibroblast growth factor 2 in growth hormone-secreting adenomas. Endocrine 52(3):632–640. https://doi.org/10.1007/s12020-015-0802-8 CrossRefPubMed Ozkaya HM, Comunoglu N, Keskin FE, Oz B, Haliloglu OA, Tanriover N, Gazioglu N, Kadioglu P (2016) Locally produced estrogen through aromatization might enhance tissue expression of pituitary tumor transforming gene and fibroblast growth factor 2 in growth hormone-secreting adenomas. Endocrine 52(3):632–640. https://​doi.​org/​10.​1007/​s12020-015-0802-8 CrossRefPubMed

go back to reference Buchbinder S, Bierhaus A, Zorn M, Nawroth PP, Humpert P, Schilling T (2008) Aryl hydrocarbon receptor interacting protein gene (AIP) mutations are rare in patients with hormone secreting or non-secreting pituitary adenomas. Exp Clin Endocrinol Diabetes 116(10):625–628. https://doi.org/10.1055/s-2008-1065366 CrossRefPubMed Buchbinder S, Bierhaus A, Zorn M, Nawroth PP, Humpert P, Schilling T (2008) Aryl hydrocarbon receptor interacting protein gene (AIP) mutations are rare in patients with hormone secreting or non-secreting pituitary adenomas. Exp Clin Endocrinol Diabetes 116(10):625–628. https://​doi.​org/​10.​1055/​s-2008-1065366 CrossRefPubMed

go back to reference Oriola J, Lucas T, Halperin I, Mora M, Perales MJ, Alvarez-Escola C, Paz deMN, Diaz Soto G, Salinas I, Julian MT, Olaizola I, Bernabeu I, Marazuela M, Puig-Domingo M (2013) Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues. Eur J Endocrinol 168(1):9–13. https://doi.org/10.1530/eje-12-0457 CrossRefPubMed Oriola J, Lucas T, Halperin I, Mora M, Perales MJ, Alvarez-Escola C, Paz deMN, Diaz Soto G, Salinas I, Julian MT, Olaizola I, Bernabeu I, Marazuela M, Puig-Domingo M (2013) Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues. Eur J Endocrinol 168(1):9–13. https://​doi.​org/​10.​1530/​eje-12-0457 CrossRefPubMed

go back to reference Ferrau F, Romeo PD, Puglisi S, Ragonese M, Torre ML, Scaroni C, Occhi G, De Menis E, Arnaldi G, Trimarchi F, Cannavo S (2016) Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study. Endocrine 54(3):762–767. https://doi.org/10.1007/s12020-016-0862-4 CrossRefPubMed Ferrau F, Romeo PD, Puglisi S, Ragonese M, Torre ML, Scaroni C, Occhi G, De Menis E, Arnaldi G, Trimarchi F, Cannavo S (2016) Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study. Endocrine 54(3):762–767. https://​doi.​org/​10.​1007/​s12020-016-0862-4 CrossRefPubMed

go back to reference Jaffrain-Rea ML, Angelini M, Gargano D, Tichomirowa MA, Daly AF, Vanbellinghen JF, D’Innocenzo E, Barlier A, Giangaspero F, Esposito V, Ventura L, Arcella A, Theodoropoulou M, Naves LA, Fajardo C, Zacharieva S, Rohmer V, Brue T, Gulino A, Cantore G, Alesse E, Beckers A (2009) Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr Relat Cancer 16(3):1029–1043. https://doi.org/10.1677/erc-09-0094 CrossRefPubMed Jaffrain-Rea ML, Angelini M, Gargano D, Tichomirowa MA, Daly AF, Vanbellinghen JF, D’Innocenzo E, Barlier A, Giangaspero F, Esposito V, Ventura L, Arcella A, Theodoropoulou M, Naves LA, Fajardo C, Zacharieva S, Rohmer V, Brue T, Gulino A, Cantore G, Alesse E, Beckers A (2009) Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr Relat Cancer 16(3):1029–1043. https://​doi.​org/​10.​1677/​erc-09-0094 CrossRefPubMed

go back to reference Cazabat L, Bouligand J, Salenave S, Bernier M, Gaillard S, Parker F, Young J, Guiochon-Mantel A, Chanson P (2012) Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. J Clin Endocrinol Metab 97(4):E663-E670. https://doi.org/10.1210/jc.2011-2291 CrossRef Cazabat L, Bouligand J, Salenave S, Bernier M, Gaillard S, Parker F, Young J, Guiochon-Mantel A, Chanson P (2012) Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. J Clin Endocrinol Metab 97(4):E663-E670. https://​doi.​org/​10.​1210/​jc.​2011-2291 CrossRef

go back to reference García-Arnés JA, González-Molero I, Oriola J, Mazuecos N, Luque R, Castaño J, Arraez MA (2013) Familial isolated pituitary adenoma caused by a AIP gene mutation not described before in a family context. Endocrine Pathol 24(4):234–238. https://doi.org/10.1007/s12022-013-9268-5 CrossRef García-Arnés JA, González-Molero I, Oriola J, Mazuecos N, Luque R, Castaño J, Arraez MA (2013) Familial isolated pituitary adenoma caused by a AIP gene mutation not described before in a family context. Endocrine Pathol 24(4):234–238. https://​doi.​org/​10.​1007/​s12022-013-9268-5 CrossRef

go back to reference Hernandez-Ramirez LC, Martucci F, Morgan RM, Trivellin G, Tilley D, Ramos-Guajardo N, Iacovazzo D, D’Acquisto F, Prodromou C, Korbonits M (2016) Rapid proteasomal degradation of mutant proteins is the primary mechanism leading to tumorigenesis in patients with missense AIP mutations. J Clin Endocrinol Metab 101(8):3144–3154. https://doi.org/10.1210/jc.2016-1307 CrossRefPubMedPubMedCentral Hernandez-Ramirez LC, Martucci F, Morgan RM, Trivellin G, Tilley D, Ramos-Guajardo N, Iacovazzo D, D’Acquisto F, Prodromou C, Korbonits M (2016) Rapid proteasomal degradation of mutant proteins is the primary mechanism leading to tumorigenesis in patients with missense AIP mutations. J Clin Endocrinol Metab 101(8):3144–3154. https://​doi.​org/​10.​1210/​jc.​2016-1307 CrossRefPubMedPubMedCentral

go back to reference Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, Berney DM, Wass JA, Popovic V, Ribeiro-Oliveira A Jr, Gadelha MR, Monson JP, Akker SA, Davis JR, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, Musat M, Flanagan D, Peters G, Bolger GB, Chapple JP, Frohman LA, Grossman AB, Korbonits M (2008) The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 93(6):2390–2401. https://doi.org/10.1210/jc.2007-2611 CrossRefPubMed Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, Berney DM, Wass JA, Popovic V, Ribeiro-Oliveira A Jr, Gadelha MR, Monson JP, Akker SA, Davis JR, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, Musat M, Flanagan D, Peters G, Bolger GB, Chapple JP, Frohman LA, Grossman AB, Korbonits M (2008) The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 93(6):2390–2401. https://​doi.​org/​10.​1210/​jc.​2007-2611 CrossRefPubMed

go back to reference Gadelha MR, Kasuki L, Korbonits M (2013) Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 24(5):238–246. https://doi.org/10.1016/j.tem.2012.11.007 CrossRefPubMed Gadelha MR, Kasuki L, Korbonits M (2013) Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 24(5):238–246. https://​doi.​org/​10.​1016/​j.​tem.​2012.​11.​007 CrossRefPubMed

go back to reference Chahal HS, Trivellin G, Leontiou CA, Alband N, Fowkes RC, Tahir A, Igreja SC, Chapple JP, Jordan S, Lupp A, Schulz S, Ansorge O, Karavitaki N, Carlsen E, Wass JA, Grossman AB, Korbonits M (2012) Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab 97(8):E1411-1420. https://doi.org/10.1210/jc.2012-1111 CrossRef Chahal HS, Trivellin G, Leontiou CA, Alband N, Fowkes RC, Tahir A, Igreja SC, Chapple JP, Jordan S, Lupp A, Schulz S, Ansorge O, Karavitaki N, Carlsen E, Wass JA, Grossman AB, Korbonits M (2012) Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab 97(8):E1411-1420. https://​doi.​org/​10.​1210/​jc.​2012-1111 CrossRef

go back to reference Iacovazzo D, Carlsen E, Lugli F, Chiloiro S, Piacentini S, Bianchi A, Giampietro A, Mormando M, Clear AJ, Doglietto F, Anile C, Maira G, Lauriola L, Rindi G, Roncaroli F, Pontecorvi A, Korbonits M, De Marinis L (2016) Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol 174(2):241–250. https://doi.org/10.1530/eje-15-0832 CrossRefPubMed Iacovazzo D, Carlsen E, Lugli F, Chiloiro S, Piacentini S, Bianchi A, Giampietro A, Mormando M, Clear AJ, Doglietto F, Anile C, Maira G, Lauriola L, Rindi G, Roncaroli F, Pontecorvi A, Korbonits M, De Marinis L (2016) Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol 174(2):241–250. https://​doi.​org/​10.​1530/​eje-15-0832 CrossRefPubMed

go back to reference Grant M, Alturaihi H, Jaquet P, Collier B, Kumar U (2008) Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol Endocrinol 22(10):2278–2292. https://doi.org/10.1210/me.2007-0334 CrossRefPubMedPubMedCentral Grant M, Alturaihi H, Jaquet P, Collier B, Kumar U (2008) Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol Endocrinol 22(10):2278–2292. https://​doi.​org/​10.​1210/​me.​2007-0334 CrossRefPubMedPubMedCentral

go back to reference Casarini AP, Jallad RS, Pinto EM, Soares IC, Nonogaki S, Giannella-Neto D, Musolino NR, Alves VA, Bronstein MD (2009) Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary 12(4):297–303. https://doi.org/10.1007/s11102-009-0175-1 CrossRefPubMed Casarini AP, Jallad RS, Pinto EM, Soares IC, Nonogaki S, Giannella-Neto D, Musolino NR, Alves VA, Bronstein MD (2009) Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary 12(4):297–303. https://​doi.​org/​10.​1007/​s11102-009-0175-1 CrossRefPubMed

go back to reference Daly AF, Tichomirowa MA, Petrossians P, Heliovaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A, Cazabat L, De Menis E, Montanana CF, Raverot G, Weil RJ, Sane T, Maiter D, Neggers S, Yaneva M, Tabarin A, Verrua E, Eloranta E, Murat A, Vierimaa O, Salmela PI, Emy P, Toledo RA, Sabate MI, Villa C, Popelier M, Salvatori R, Jennings J, Longas AF, Labarta Aizpun JI, Georgitsi M, Paschke R, Ronchi C, Valimaki M, Saloranta C, De Herder W, Cozzi R, Guitelman M, Magri F, Lagonigro MS, Halaby G, Corman V, Hagelstein MT, Vanbellinghen JF, Barra GB, Gimenez-Roqueplo AP, Cameron FJ, Borson-Chazot F, Holdaway I, Toledo SP, Stalla GK, Spada A, Zacharieva S, Bertherat J, Brue T, Bours V, Chanson P, Aaltonen LA, Beckers A (2010) Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 95(11):E373-383. https://doi.org/10.1210/jc.2009-2556 CrossRef Daly AF, Tichomirowa MA, Petrossians P, Heliovaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A, Cazabat L, De Menis E, Montanana CF, Raverot G, Weil RJ, Sane T, Maiter D, Neggers S, Yaneva M, Tabarin A, Verrua E, Eloranta E, Murat A, Vierimaa O, Salmela PI, Emy P, Toledo RA, Sabate MI, Villa C, Popelier M, Salvatori R, Jennings J, Longas AF, Labarta Aizpun JI, Georgitsi M, Paschke R, Ronchi C, Valimaki M, Saloranta C, De Herder W, Cozzi R, Guitelman M, Magri F, Lagonigro MS, Halaby G, Corman V, Hagelstein MT, Vanbellinghen JF, Barra GB, Gimenez-Roqueplo AP, Cameron FJ, Borson-Chazot F, Holdaway I, Toledo SP, Stalla GK, Spada A, Zacharieva S, Bertherat J, Brue T, Bours V, Chanson P, Aaltonen LA, Beckers A (2010) Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 95(11):E373-383. https://​doi.​org/​10.​1210/​jc.​2009-2556 CrossRef

go back to reference Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A, Papotti M (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20(11):1172–1182. https://doi.org/10.1038/modpathol.3800954 CrossRefPubMed Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A, Papotti M (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20(11):1172–1182. https://​doi.​org/​10.​1038/​modpathol.​3800954 CrossRefPubMed

go back to reference Pisarek H, Pawlikowski M, Kunert-Radek J, Kubiak R, Winczyk K (2010) SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors. Folia Histochem Cytobiol 48(1):142–147. https://doi.org/10.2478/v10042-008-0103-7 CrossRefPubMed Pisarek H, Pawlikowski M, Kunert-Radek J, Kubiak R, Winczyk K (2010) SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors. Folia Histochem Cytobiol 48(1):142–147. https://​doi.​org/​10.​2478/​v10042-008-0103-7 CrossRefPubMed

go back to reference Pisarek H, Pawlikowski M, Kunert-Radek J, Winczyk K (2010) Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5? Endokrynol Pol 61(2):178–181PubMed Pisarek H, Pawlikowski M, Kunert-Radek J, Winczyk K (2010) Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5? Endokrynol Pol 61(2):178–181PubMed

go back to reference Reubi JC, Waser B, Liu Q, Laissue JA, Schonbrunn A (2000) Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. J Clin Endocrinol Metab 85(10):3882–3891. https://doi.org/10.1210/jcem.85.10.6864 PubMedCrossRef Reubi JC, Waser B, Liu Q, Laissue JA, Schonbrunn A (2000) Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. J Clin Endocrinol Metab 85(10):3882–3891. https://​doi.​org/​10.​1210/​jcem.​85.​10.​6864 PubMedCrossRef

go back to reference Pawlikowski M, Pisarek H, Kunert-Radek J, Radek M (2008) Somatostatin receptors in GH-secreting pituitary adenomas–their relationship to the response to octreotide. Endokrynol Pol 59(3):196–199PubMed Pawlikowski M, Pisarek H, Kunert-Radek J, Radek M (2008) Somatostatin receptors in GH-secreting pituitary adenomas–their relationship to the response to octreotide. Endokrynol Pol 59(3):196–199PubMed

go back to reference Ritvonen E, Pitkanen E, Karppinen A, Vehkavaara S, Demir H, Paetau A, Schalin-Jantti C, Karhu A (2017) Impact of AIP and inhibitory G protein alpha 2 proteins on clinical features of sporadic GH-secreting pituitary adenomas. Eur J Endocrinol 176(2):243–252. https://doi.org/10.1530/eje-16-0620 CrossRefPubMed Ritvonen E, Pitkanen E, Karppinen A, Vehkavaara S, Demir H, Paetau A, Schalin-Jantti C, Karhu A (2017) Impact of AIP and inhibitory G protein alpha 2 proteins on clinical features of sporadic GH-secreting pituitary adenomas. Eur J Endocrinol 176(2):243–252. https://​doi.​org/​10.​1530/​eje-16-0620 CrossRefPubMed

go back to reference Wildemberg LEA, Neto LV, Costa DF, Nasciuti LE, Takiya CM, Alves LM, Rebora A, Minuto F, Ferone D, Gadelha MR (2013) Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J Endocrinol Invest 36(1):38–43. https://doi.org/10.3275/8305 PubMedCrossRef Wildemberg LEA, Neto LV, Costa DF, Nasciuti LE, Takiya CM, Alves LM, Rebora A, Minuto F, Ferone D, Gadelha MR (2013) Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J Endocrinol Invest 36(1):38–43. https://​doi.​org/​10.​3275/​8305 PubMedCrossRef